Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioACET +0.06%34 EV-to-EBIT is 0.28 as of Aug. 13, 2026, which is 85% below its 10-year median of 1.88. GuruFocus rates ACET with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 367 Biotechnology companies, Adicet Bio ranks better than 89.1% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Adicet Bio's Enterprise Value for the quarter that ended in Jun. 2026 was $-24.46 Mil.
Adicet Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio EV-to-EBIT Related Terms
Adicet Bio EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Adicet Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adicet Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Adicet Bio's EV-to-EBIT falls into.
Adicet Bio's current Enterprise Value is $-28.01 Mil.
Adicet Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (ACET) has a EV-to-EBIT of 0.28 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adicet Bio and its competitors. This is 85% below median its historical median of 1.88. According to the industry distribution chart, Adicet Bio ranks #40 out of 367 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Adicet Bio's EV-to-EBIT too high?
Adicet Bio's current EV-to-EBIT of 0.28 is 85% below median its 10-year median of 1.88. The Biotechnology industry median EV-to-EBIT is 15.42. Adicet Bio's value of 0.28 is 98.2% below this industry median. Based on the distribution chart, Adicet Bio ranks #40 out of 367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adicet Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's EV-to-EBIT compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #40 out of 367 companies for EV-to-EBIT. This places Adicet Bio in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.42. Adicet Bio's value of 0.28 is 98.2% below this benchmark. While the company's 10-year median is 1.88 vs. the industry median of 15.42, Adicet Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.42, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current EV-to-EBIT of 0.28 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current EV-to-EBIT is 0.28, which is 85% below median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (ACET) has a current EV-to-EBIT of 0.28. The current EV-to-EBIT is 0.28, which is 85% below median its 10-year median of 1.88 and 98.2% below the Biotechnology industry median of 15.42. Adicet Bio's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Adicet Bio (ACET), the current EV-to-EBIT is 0.28 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
34GF Score
Get the complete analysis for ACET
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACET has been successfully added to your 
